Control, Communication, and Care: Assistive BCIs and the Rise of Thoughtful Interfaces – Issue #32
Welcome to Neurotech Pulse – Issue #32! This edition reflects neurotech’s steady progression from early-stage exploration to clinical and commercial execution. From Paradromics’ FDA greenlight for its speech-restoring implant and ONWARD’s at-home spinal cord therapy approval to INBRAIN’s AI partnership with Microsoft and Phantom Neuro’s patient registry launch, the field continues to bridge neuroscience, devices, and real-world care.
Funding momentum from Synchron, Beacon Biosignals, and Coherence Neuro highlights investor confidence in scalable BCI systems, neural diagnostics, and brain-guided therapies. We also explore emerging trends in ethics, ambient interfaces, and hybrid brain–device architectures, alongside breakthroughs in transformer-powered EEG decoding, subretinal prosthetics, and lab-grown brain organoids.
This issue’s Case Study Spotlight features Cognixion, a California-based company building non-invasive BCIs that help people speak using only brain and eye signals. By combining EEG, AR, and gaze tracking into a wearable system, Cognixion is rethinking how communication can be restored without implants or muscle movement.
⚡️Neurotech Newsflash
Paradromics gets FDA approval for the first human trial of its Connexus BCI (speech restoration): Paradromics has secured FDA Investigational Device Exemption (IDE) approval for its Connect-One Early Feasibility Study. The study will evaluate the Connexus BCI, a high-bandwidth neural implant designed to restore speech in individuals with severe motor impairment. First-in-human trials are expected to begin in early 2026. (Read more)
ONWARD Medical receives FDA 510(k) clearance for at-home use of its ARC-EX system (spinal cord injury rehabilitation): ONWARD’s ARC-EX system, a non-invasive neuromodulation device for spinal cord injury (SCI), has been cleared for home use by the FDA, enabling patients to continue therapy outside clinical settings. The company also received IDE approval to begin a pivotal study of its implanted ARC-IM system focused on blood pressure stabilization in SCI patients. (Read more)
Phantom Neuro launches Patient Registry for upcoming neural interface trials: Phantom Neuro has opened enrollment for its Patient Registry, inviting upper-limb amputees to participate in upcoming studies. The initiative supports clinical validation of Phantom’s minimally invasive neural interfaces aimed at intuitive prosthetic control. (Read more)
INBRAIN Neuroelectronics partners with Microsoft on agentic AI for BCI therapeutics: INBRAIN is collaborating with Microsoft to develop agentic AI systems that power precision neurology. The partnership combines INBRAIN’s graphene-based neural interfaces with Microsoft’s cloud and AI infrastructure, accelerating personalized brain therapies. (Read more)
💰Notable Funding
Synchron raises $200M Series D to scale Stentrode and launch new BCI platform: Synchron announced a $200M round led by Double Point Ventures, with continued backing from ARCH, Khosla Ventures, Jeff Bezos, and Protocol Labs. The funds will accelerate commercialization of its Stentrode BCI system and support development of a stealth-mode, high-channel, whole-brain interface. Synchron also plans to open a new R&D facility in San Diego to drive next-gen platform innovation. (Read more)
Beacon Biosignals raises $86M Series B to expand AI-powered brain diagnostics: Backed by ARCH Venture Partners, the round will be used to scale Beacon’s EEG-based precision neurology platform, grow its proprietary neurodiagnostic datasets, and accelerate the development of AI-derived biomarkers for brain and mental health disorders. (Read more)
Coherence Neuro raises $10 M to launch closed-loop neuro system for cancer treatment: San Francisco-based Coherence Neuro has secured a $10 million seed round from Babel Ventures to advance its work at the intersection of neuroengineering and cancer therapy. This latest funding will enable the company to begin its first human trials, a pivotal step toward building a closed-loop, bi-directional system for treating cancer. (Read more)
EBRAINS-Neurotech awarded €18.3M grant to build next‑gen brain technology infrastructure: A new European consortium, EBRAINS‑Neurotech, led by the University of Amsterdam and 8 other institutions has secured funding from the Dutch Research Council (NWO) to build shared infrastructure for brain‑machine interface research, advanced neural implants, and digital brain models. (Read more)
NextSense raises $16M Series A to launch EEG-smartbuds for everyday brain monitoring: Led by Creation Partners, the round will support the commercial launch and scale-up of NextSense’s EEG-enabled smart earbuds, designed to passively monitor brain activity during sleep, focus, and daily life. The funding will also help expand developer tools and accelerate clinical research partnerships. (Read more)
Precision Neuroscience receives investment from SCI Ventures to accelerate BCI access for paralysis: Precision Neuroscience has partnered with SCI Ventures, a firm focused on spinal cord injury innovation, to expand the clinical deployment of its Layer 7 cortical interface. The funds will support clinical studies, regulatory progress, and broader access to brain-computer interface technology for individuals with severe paralysis. (Read more)
🧠 Neurotech Trends:
UNESCO Adopts Global Ethics Standard for Neurotechnology: In a landmark move, UNESCO has adopted the world’s first international ethical framework for neurotechnology. The guidelines emphasize mental privacy, cognitive liberty, and protection from coercive or exploitative use, laying down ethical boundaries for neural data collection, workplace surveillance, and military applications. (Read more)
Global BCI market projected to grow from ~$2.4B (2025) to ~$6.16B by 2032, fueled by Non-Invasive Solutions: A recent market analysis projects the global brain-computer interface market to grow from ~$2.4B in 2025 to ~$6.16B by 2032, driven by regulatory progress, broader neurological applications, and a surge in wearable and non-invasive systems. The forecast reflects rising confidence in neurotech’s shift from experimental to essential. (Read more)
Apple Vision Pro Explores Accessibility via Non-Invasive Brain Interfaces: Apple’s accessibility team has begun experimenting with Vision Pro as a hands-free interface platform, leveraging gaze tracking and neural signal interpretation for users with motor impairments. Early pilots suggest that non-invasive brain-computer interaction could evolve through ambient sensors and attention-based triggers—transforming assistive tech into a seamless, mainstream experience (Read more)
📘 Neurotech Articles:
Lab-Grown Brain Organoids mimic early Human Cognition:Researchers from UC Santa Cruz found that human brain organoids (grown from stem cells and isolated from all sensory input) produce structured, time‑based neuronal firing patterns resembling the brain’s default mode. These early sequences emerge months before sensory processing is possible, suggesting the brain assembles its foundational circuitry from an intrinsic, genetically guided program. The work provides a controlled model for studying early neurodevelopment, disorders, and the impact of toxins on fetal brain wiring. (Read more)
Sleep Apnea may be a precursor to Parkinson’s Disease: A longitudinal study of over 11million adults found that individuals with obstructive sleep apnea (OSA) were significantly more likely to develop Parkinson’s disease — independent of age, sex, and other risk factors. The research highlights a potential neurodegenerative pathway triggered by chronic sleep disruption and positions respiratory irregularities during sleep as an early biomarker for Parkinsonian disorders. (Read more)
Genetic risk combined with cardiovascular factors may help predict and delay dementia: A new study led by UC San Francisco shows that dementia risk prediction improves significantly when genetic factors are combined with cardiovascular health markers. While genes like APOE4 and family history carry weight, modifiable risks, such as hypertension, obesity, and diabetes proved equally important. The findings point toward more personalized, prevention-focused strategies for identifying those at highest risk. (Read more)
Guidewire‑deployable high‑density ECoG array enables scalable BCI implants: A team of researchers published a novel electrocorticography (ECoG) array that packs 256 electrodes in 4 cm², can be folded, inserted via a millimeter‑scale skull opening, then unfurled epidurally. In canine tests it captured rich auditory neural signals and, using standard ML classifiers, could distinguish between sound types with > 80% accuracy. This design resolves a longstanding tradeoff between electrode coverage, signal fidelity, and surgical invasiveness, a key enabler for future, scalable brain‑computer interfaces. (Read more)
Transformer‑integrated deep‑learning enables robust EEG decoding of complex visual imagery: In a new study, researchers introduced a deep learning architecture that combines functional connectivity metrics with a convolutional neural network and image transformer hybrid. Applied to non-invasive EEG recordings, the system decodes complex visual imagery (such as imagined upper-limb movements) into control signals for robotic arm manipulation. Offline and pseudo-online tests showed promising subject-independent decoding, marking a step toward versatile, non-invasive BCI interfaces that do not require implants. (Read more)
🌐 Neurotech Edu. and Events:
NeurIPS 2025
📅 Date: December 02–07, 2025 | 📍 San Diego, USA NeurIPS+1Why Attend the Event?
Join neuroscientists, ML researchers, and neurotech innovators at NeurIPS 2025, the world’s leading conference on neural information processing. While known for frontier AI work, its dedicated tracks on computational neuroscience, neural decoding, and brain-inspired architectures are where the next wave of BCI algorithms are born. Expect sessions on spiking neural networks, neural representation learning, semantic decoding from EEG, and biologically grounded AI.
Link to register: Register here
EBRAINS Summit 2025
📅 Date: December 08–11, 2025 | 📍 Brussels, BelgiumWhy Attend the Event?
Join neuroinformaticians, brain researchers, and policy leaders for the EBRAINS Summit 2025, focused on building Europe’s digital neuroscience infrastructure. This year’s edition will spotlight the EBRAINS 2.0 roadmap, advancing cross-border brain data sharing, simulation engines, and ultra-detailed brain atlases. Sessions explore how open-access neural platforms are powering both clinical research and next-gen neurotechnologies.Link to register: Register here
CIFAR Neuroscience of Consciousness Winter School
📅 Date: December 10–12, 2025 | 📍 Montebello, CanadaWhy Attend the Event?
Join neuroscientists, philosophers, and AI researchers at this intimate CIFAR winter workshop exploring the biology of consciousness. Hosted by the Brain, Mind & Consciousness program, the event brings together leading voices tackling the “hard problem” of subjective experience. Sessions delve into cross-species neural correlates of consciousness, selfhood, memory, and what it means for the future of sentient AI systems.Link to register: Register here
🎬Case Studies
🎬 Case Study Spotlight: Cognixion – Non-Invasive BCI for Assistive Communication
In this edition’s case study spotlight, we feature Cognixion, a California-based neurotechnology company advancing brain–computer interfaces for individuals with severe motor and speech impairments. Cognixion is developing Cognixion ONE, a non-invasive, wearable system that combines EEG, eye tracking, and augmented reality to enable communication through neural and gaze-based intent. By integrating multiple input modalities into a portable, AI-assisted interface, the platform offers a new pathway for restoring speech without relying on muscle movement or invasive implants.
Currently offered for research and investigational use, Cognixion ONE is being evaluated in clinical environments, with the aim of enabling real-world application across assistive care, neurorehabilitation, and speech therapy.
Overview:
Cognixion ONE pairs a wireless EEG headset (Axon-R) with an AR-enabled display to detect and interpret user intent using a combination of brain activity, gaze fixation, and head pose. The system supports predictive text generation, personalized voice synthesis, and real-time interaction via a fully embedded, multimodal interface.
Designed for individuals with conditions such as ALS, cerebral palsy, or spinal cord injury, the platform operates without surgical intervention and is optimized for deployment in home and clinical settings. A clinical study integrating Cognixion ONE with Apple Vision Pro is currently underway to explore spatial computing applications for non-verbal communication.
Use Case Highlights:
Assistive Communication: Enables speech generation using neural and gaze signals in individuals with minimal or no voluntary movement.
Supports Multimodal Input: Combines EEG, eye tracking, and head tracking to improve accuracy and reduce false selections.
Non-Invasive and Portable: Offers a fully wearable, wireless BCI system designed for real-world environments without surgical procedures.
Voice Personalization: Supports custom voice proxies for identity-preserving speech synthesis in degenerative conditions.
Target Audience:
Clinicians and speech-language pathologists supporting patients with neuromuscular or motor impairments
Rehabilitation centers and long-term care facilities seeking non-invasive AAC (augmentative and alternative communication) solutions
Neurotechnology researchers developing multimodal BCI systems for assistive and clinical applications
Key Partnerships:
Cognixion has partnered with Pupil Labs for integrated eye-tracking support and Blackrock Neurotech for research distribution of the Axon-R platform. A clinical collaboration with Apple Vision Pro is underway to evaluate spatial computing interfaces for non-verbal users.
Leadership Team:
Cognixion is led by Andreas Forsland (Founder & CEO), whose experience as a caregiver informed the company’s mission, and Chris Ullrich (CTO), who brings technical leadership across biosignals, AR, and embedded systems. The team spans neuroscience, clinical design, and real-time systems engineering.
For more information about Cognixion and its non-invasive BCI platform, visit cognixion.com
🌟 Neurotech Pulse Special Edition: Call for Contributions!
Calling all researchers and writers! Want to showcase your work in our upcoming Neurotech Insights edition? Reach over 5,000+ neurotech enthusiasts by sharing your innovative research. Submit your details and work to collaboration@nexstem.ai
❤️ Join us on Discord.
Thanks for reading Neurotech Pulse! Subscribe for free to receive new posts.